Viking Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Viking Therapeutics, Inc. (VKTX) reported Increase (Decrease) in Accrued Liabilities of $17.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-07-29
- Viking Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $1.34M, a 90.84% decline year-over-year.
- Viking Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $15.86M.
- Viking Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.07M.
- Viking Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$4.80M, a 142.57% decline year-over-year.
- Viking Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $6.17M, a 6.05% increase from fiscal 2024.
- Viking Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $5.82M.
- Viking Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$1.82M, a 131.26% decline from fiscal 2022.
- Viking Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $5.81M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $17.20M 10-Q · filed 2026-07-29 | $19.27M derived: sum of 3 quarters · filed 2026-07-29 | $14.47M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $15.86M 10-Q · filed 2026-04-30 | $17.93M derived: sum of 2 quarters · filed 2026-04-30 | $13.13M derived: sum of 3 quarters · filed 2026-04-30 | $27.77M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$2.74M derived: sum of 2 quarters · filed 2026-02-11 | $11.91M derived: sum of 3 quarters · filed 2026-07-29 | $6.17M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | -$4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $9.84M derived: sum of 2 quarters · filed 2026-07-29 | $4.10M 10-Q · filed 2025-10-23 | -$3.73M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $14.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $8.90M 10-Q · filed 2026-07-29 | $1.07M derived: sum of 3 quarters · filed 2026-07-29 | $12.35M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | -$5.74M 10-Q · filed 2026-04-30 | -$13.57M derived: sum of 2 quarters · filed 2026-04-30 | -$2.29M derived: sum of 3 quarters · filed 2026-04-30 | -$15.85M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | -$7.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $3.44M derived: sum of 2 quarters · filed 2026-02-11 | -$10.11M derived: sum of 3 quarters · filed 2026-02-11 | $5.82M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $11.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | -$2.27M derived: sum of 2 quarters · filed 2025-10-23 | $13.65M 10-Q · filed 2025-10-23 | $17.57M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | -$13.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-23 | $2.37M 10-Q · filed 2025-07-23 | $6.29M derived: sum of 3 quarters · filed 2026-02-11 | $6.12M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $15.92M 10-Q · filed 2025-04-24 | $19.84M derived: sum of 2 quarters · filed 2026-02-11 | $19.67M derived: sum of 3 quarters · filed 2026-02-11 | $15.68M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $3.75M derived: sum of 2 quarters · filed 2026-02-11 | -$244.00K derived: sum of 3 quarters · filed 2026-02-11 | -$1.82M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | -$177.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-23 | -$4.17M derived: sum of 2 quarters · filed 2024-10-23 | -$5.74M 10-Q · filed 2024-10-23 | -$3.24M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | -$3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | -$5.56M 10-Q · filed 2024-07-24 | -$3.07M derived: sum of 3 quarters · filed 2025-02-26 | -$969.00K derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | -$1.57M 10-Q · filed 2024-04-25 | $922.00K derived: sum of 2 quarters · filed 2025-02-26 | $3.02M derived: sum of 3 quarters · filed 2025-02-26 | $3.54M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $4.59M derived: sum of 2 quarters · filed 2025-02-26 | $5.12M derived: sum of 3 quarters · filed 2025-02-26 | $5.81M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | $2.62M derived: sum of 2 quarters · filed 2023-10-25 | $3.31M 10-Q · filed 2023-10-25 | |||||
| 2022-06-30 | $523.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | $1.22M 10-Q · filed 2023-07-26 | ||||||
| 2022-03-31 | $694.00K 10-Q · filed 2023-04-26 | |||||||
| 2021-12-31 | -$506.00K 10-K · filed 2024-02-07 | |||||||
| 2020-12-31 | $3.77M 10-K · filed 2022-02-09 | |||||||
| 2020-06-30 | -$356.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $1.48M 10-Q · filed 2020-07-29 | $32.00K derived: sum of 3 quarters · filed 2021-02-17 | $2.01M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2020-03-31 | $1.84M 10-Q · filed 2020-04-30 | $388.00K derived: sum of 2 quarters · filed 2021-02-17 | $2.37M derived: sum of 3 quarters · filed 2021-02-17 | $2.43M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $527.00K derived: sum of 2 quarters · filed 2021-02-17 | $591.00K derived: sum of 3 quarters · filed 2021-02-17 | $423.00K 10-K · filed 2021-02-17 | $2.39M 10-K · filed 2020-02-26 | |||
| 2019-09-30 | $1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $2.04M derived: sum of 2 quarters · filed 2020-07-29 | $1.88M 10-Q · filed 2019-11-05 | $2.21M derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-06-30 | $64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | -$104.00K 10-Q · filed 2020-07-29 | $592.00K 10-Q · filed 2019-08-01 | $233.00K derived: sum of 3 quarters · filed 2020-07-29 | $1.25M derived: sum of 4 quarters · filed 2020-07-29 | |||
| 2019-03-31 | -$168.00K 10-Q · filed 2020-04-30 | -$118.00K 10-Q · filed 2019-05-02 | $169.00K derived: sum of 2 quarters · filed 2020-04-30 | $1.18M derived: sum of 3 quarters · filed 2020-04-30 | $1.73M derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-12-31 | $337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $1.35M derived: sum of 2 quarters · filed 2020-02-26 | $1.90M derived: sum of 3 quarters · filed 2020-02-26 | $1.47M 10-K · filed 2020-02-26 | ||||
| 2018-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $1.56M derived: sum of 2 quarters · filed 2019-11-05 | $1.13M 10-Q · filed 2019-11-05 | $654.00K derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $544.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $116.00K 10-Q · filed 2019-08-01 | -$361.00K derived: sum of 3 quarters · filed 2019-08-01 | -$43.00K derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2018-03-31 | -$428.00K 10-Q · filed 2019-05-02 | -$905.00K derived: sum of 2 quarters · filed 2019-05-02 | -$587.00K derived: sum of 3 quarters · filed 2019-05-02 | $110.00K derived: sum of 4 quarters · filed 2019-05-02 | ||||
| 2017-12-31 | -$477.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$159.00K derived: sum of 2 quarters · filed 2019-03-13 | $538.00K derived: sum of 3 quarters · filed 2019-03-13 | $1.01M 10-K · filed 2019-03-13 | $1.01M 10-K · filed 2018-03-07 | |||
| 2017-09-30 | $318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $1.01M derived: sum of 2 quarters · filed 2018-11-07 | $1.49M 10-Q · filed 2018-11-07 | $1.49M 10-Q · filed 2017-11-08 | $1.77M derived: sum of 4 quarters · filed 2018-11-07 | |||
| 2017-06-30 | $697.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.17M 10-Q · filed 2018-08-09 | $1.17M 10-Q · filed 2017-08-09 | $1.45M derived: sum of 3 quarters · filed 2018-08-09 | $1.70M derived: sum of 4 quarters · filed 2018-08-09 | |||
| 2017-03-31 | $472.00K 10-Q · filed 2018-05-09 | $472.14K 10-Q · filed 2017-05-10 | $753.70K derived: sum of 2 quarters · filed 2018-05-09 | $1.01M derived: sum of 3 quarters · filed 2018-05-09 | $1.08M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2016-12-31 | $281.70K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $534.09K derived: sum of 2 quarters · filed 2018-03-07 | $611.38K derived: sum of 3 quarters · filed 2018-03-07 | -$141.29K 10-K · filed 2018-03-07 | ||||
| 2016-09-30 | $252.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $329.68K derived: sum of 2 quarters · filed 2017-11-08 | -$423.00K 10-Q · filed 2017-11-08 | -$107.42K derived: sum of 4 quarters · filed 2017-11-08 | ||||
| 2016-06-30 | $77.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$675.38K 10-Q · filed 2017-08-09 | -$359.80K derived: sum of 3 quarters · filed 2017-08-09 | $692.71K derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-03-31 | -$752.68K 10-Q · filed 2017-05-10 | -$437.10K derived: sum of 2 quarters · filed 2017-05-10 | $615.41K derived: sum of 3 quarters · filed 2017-05-10 | $744.69K derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | $315.58K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $1.37M derived: sum of 2 quarters · filed 2017-03-21 | $1.50M derived: sum of 3 quarters · filed 2017-03-21 | $1.56M 10-K · filed 2017-03-21 | ||||
| 2015-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.18M derived: sum of 2 quarters · filed 2016-11-10 | $1.24M 10-Q · filed 2016-11-10 | $1.09M derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | $129.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $191.99K 10-Q · filed 2016-08-11 | $32.74K derived: sum of 3 quarters · filed 2016-08-11 | $228.04K derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | $62.71K 10-Q · filed 2016-05-10 | -$96.54K derived: sum of 2 quarters · filed 2016-05-10 | $98.76K derived: sum of 3 quarters · filed 2016-05-10 | $141.10K derived: sum of 4 quarters · filed 2016-05-10 | ||||
| 2014-12-31 | -$159.24K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $36.05K derived: sum of 2 quarters · filed 2016-03-08 | $78.40K derived: sum of 3 quarters · filed 2016-03-08 | $80.97K 10-K · filed 2016-03-08 | ||||
| 2014-09-30 | $195.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $237.64K derived: sum of 2 quarters · filed 2015-11-05 | $240.22K 10-Q · filed 2015-11-05 | |||||
| 2014-06-30 | $42.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $44.92K 10-Q · filed 2015-08-14 | ||||||
| 2014-03-31 | $2.58K 10-Q · filed 2015-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |